American Joint Committee on Cancer. Stomach Cancer. In: AJCC Cancer Staging Manual. 7th ed. New York, NY: Springer; 2010: 117–121.
Avital I, Pisters PWT, Kelsen DP, Willett CG. Cancer of the stomach, In: DeVita VT, Lawrence TS, Rosenberg SA, eds. DeVita, Hellman, and Rosenberg’s Cancer: Principles and Practice of Oncology. 9th ed. Philadelphia, Pa: Lippincott Williams & Wilkins; 2011.
Bae J, Lee E, Guyatt G. Citrus fruit intake and stomach cancer risk: A quantitative systematic review. Gastric Cancer. 2008;11:23–32.
Bang YJ, Van Cutsem E, Feyereislova A, et al. Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): A phase 3, open-label, randomized controlled trial. Lancet. 2010;376:687−697.
Bendell J. Latest data on the treatment of upper gastrointestinal cancers. ASCO Education Book 2008:184−190.
Benusiglio PR, Malka D, Rouleau E, et al. CDH1 germline mutations and the hereditary diffuse gastric and lobular breast cancer syndrome: a multicentre study. J Med Genet. 2013 Jul;50(7):486-9. Epub 2013 May 25.
Brooks-Wilson AR, Kaurah P, Suriano G, et al. Germline E-cadherin mutations in hereditary diffuse gastric cancer: Assessment of 42 new families and review of genetic screening criteria. J Med Genet. 2004;41:508–517.
Capelle LG, de Vries AC, Looman CW, et al. Gastric MALT lymphoma: Epidemiology and high adenocarcinoma risk in a nation-wide study. Eur J Cancer. 2008;44:2470–2476.
Cunningham D, Allum W, Stenning S et al. Perioperative chemotherapy vs surgery alone for resectable gastroesophageal cancer. N Eng J Med. 2006;355:11–20.
Dhalla F, da Silva SP, Lucas M, Travis S, Chapel H. Review of gastric cancer risk factors in patients with common variable immunodeficiency disorders, resulting in a proposal for a surveillance programme. Clin Exp Immunol. 2011;165:1−7.
Fuchs CS, Tomasek J, Yong CJ, et al. Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial. Lancet. 2014 Jan 4;383(9911):31-9. Epub 2013 Oct 3.
Fukase K, Kato M, Kikuchi S, et al. Effect of eradication of Helicobacter pylori on incidence of metachronous gastric carcinoma after endoscopic resection of early gastric cancer: An open-label, randomised controlled trial. Lancet. 2008;372:392–397.
Gunderson LL, Donohue JH, Alberts SR. Cancer of the Stomach. In: Abeloff MD, Armitage JO, Lichter AS, Niederhuber JE. Kastan MB, McKenna WG, eds. Abeloff’s Clinical Oncology. 4th ed. Philadelphia, Pa: Elsevier; 2008:1431–1464.
Hohenberger P, Gretschel S. Gastric cancer. Lancet. 2003;362:305–315.
Howlader N, Noone AM, Krapcho M, Garshell J, Miller D, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA (eds). SEER Cancer Statistics Review, 1975-2011, National Cancer Institute. Bethesda, MD, http://seer.cancer.gov/csr/1975_2011/, based on November 2013 SEER data submission, posted to the SEER web site, April 2014.
Hundahl SA, Phillips JL, Menck HR. The National Cancer Data Base report on poor survival of U.S. gastric cancer patients treated with gastrectomy. Cancer. 2000;88:921–932.
Huscher CG, Mingoli A, Sgarzini G, et al. Laparoscopic versus open subtotal gastrectomy for distal gastric cancer: Five-year results of a randomized prospective trial. Ann Surg. 2005;241:232–237.
Hwang J. Resectable esophageal, gastroesophageal and gastric cancers: Therapy is distinct for gastric cancer. ASCO Education Book 2008:172–176.
Jeung H, Moon Y, Rha S, et al. Phase III trial of adjuvant 5-flourouracil and adriamycin versus 5-flourouracil and adriamycin and polyadenylic-polyuridylic acid (poly a:u) for locally advanced gastric cancer after curative surgery: Final results of 15 year follow-up. Annals of Oncology. 2008;19:520–526.
Kang YK, Yook JH, Chang HM, Ryu MH, Yoo C, Zang DY, Lee JL, Kim TW, Yang DH, Jang SJ, Park YS, Lee YJ, Jung HY, Kim JH, Kim BS. Enhanced efficacy of postoperative adjuvant chemotherapy in advanced gastric cancer: results from a phase 3 randomized trial (AMC0101). Cancer Chemother Pharmacol. 2014 Jan;73(1):139-49. Epub 2013 Oct 27.
Kappas AM, Roukos DH. Quality of surgery determinant for the outcome of patient with gastric cancer. Ann Surg Oncol. 2002;9:828–830.
Koizumi W, Akiya T, HaraT et al. S-1 plus cisplatin versus S-1 alone for first line treatment of advanced gastric cancer (SPIRITS trial): A phase III trial. Lancet Oncol. 2008;9:215–221.
MacDonald JS, et al. Chemoradiotherapy after surgery compared with surgery alone for adenocarcinoma of the stomach or gastroesophageal junction. New Engl J Med. 2001;345:725–730.
Märkl B, Moldovan AI, Jähnig H, et al. Combination of ex vivo sentinel lymph node mapping and methylene blue-assisted lymph node dissection in gastric cancer: a prospective and randomized study. Ann Surg Oncol. 2011;18:1860−1868.
Masciari S, Dewanwala A, Stoffel EM, et al. Gastric cancer in individuals with Li-Fraumeni syndrome. Genet Med. 2011;13:651–657.
Muro K, Boku N, Yamada Y et al. Multicenter phase II study of RAD001 for previously treated metastatic gastric cancer: Preliminary results. J Clin Oncol. 2008;26 (May 20 suppl; abstr 4541).
National Cancer Institute. Physician Data Query (PDQ). Gastric Cancer Treatment. 2/27/2014. Accessed at: www.cancer.gov/cancertopics/pdq/treatment/gastric/HealthProfessional on April 24, 2014.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Gastric Cancer. v.2.2013. Accessed at www.nccn.org/professionals/physician_gls/pdf/gastric.pdf on April 24, 2014.
Pozzo C, Barone C. Is there an optimal chemotherapy regimen for the treatment of advanced gastric cancer that will provide a platform for the introduction of new biological agents? Oncologist. 2008;13:794–806.
Sousa H, Pinto-Correia AL, Medeiros R, Dinis-Ribeiro M. Epstein-Barr virus is associated with gastric carcinoma: The question is what is the significance? World J Gastroenterol. 2008;14:4347–4351.
Tian W, Zhao Y, Liu S, Li X. Meta-analysis on the relationship between nonsteroidal anti-inflammatory drug use and gastric cancer. Eur J Cancer Prev. 2010;19:288–298.
Wong H, Yau T. Targeted therapy in the management of advanced gastric cancer: Are we making progress in the era of personalized medicine? Oncologist. 2012;17:346–358.
Yang P, Zhou Y, Chen B, et al. Overweight, obesity and gastric cancer risk: Results from a meta-analysis of cohort studies. Eur J Cancer. 2009;45:2867–2873.
Last Revised: 02/11/2016